Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.18 | N/A | +35.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.18 | N/A | +35.71% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about the company's future, emphasizing their commitment to innovation and strategic initiatives.
Management highlighted ongoing progress in pipeline development.
They noted the importance of strategic partnerships for future growth.
Alkermes' earnings report showed a positive surprise on EPS, which contributed to a 6.3% increase in stock price. Investors reacted favorably to the management's comments about progress in their pipeline and strategic partnerships. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EDWARDS LIFESCIENCES
Oct 26, 2015